Aptinyx Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • APTX

Stock Symbol

  • Share Price
  • $0.10
  • (As of Friday Closing)

Aptinyx General Information

Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Contact Information

Website
www.aptinyx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PINX
Corporate Office
  • 909 Davis Street
  • Suite 600
  • Evanston, IL 60201
  • United States
+1 (847) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aptinyx Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.10 $0.09 $6.5M 67.7M 121K -$0.98

Aptinyx Financials Summary

In Thousands,
USD
TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (22,851) (22,556) 69,549 115,058
Revenue 0 0 1,000 1,564
EBITDA (62,400) (61,630) (73,774) (49,553)
Net Income (66,088) (64,849) (74,886) (50,053)
Total Assets 47,963 66,684 114,928 150,606
Total Debt 27,176 24,903 14,155 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aptinyx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial

Aptinyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial

Aptinyx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Drug Discovery
Evanston, IL
12 As of 2022
00000
00000000 00000

000000

t amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
0000000000000
Zug, Switzerland
000 As of 0000
00000
000000000 00000

000000

it, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim a
0000 000000000
Framingham, MA
00 As of 0000
00000
0.000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aptinyx Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Alzheon Venture Capital-Backed Framingham, MA 00 00000 00000000000 00000
VistaGen Therapeutics Corporation South San Francisco, CA 00 0000 00000000 0000
Vertex Pharmaceuticals Formerly VC-backed Boston, MA 0000 00.000 000000&0
Neurogene Formerly VC-backed New York, NY 00 00000 000000000 00000
You’re viewing 5 of 61 competitors. Get the full list »

Aptinyx Patents

Aptinyx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4161517-A2 Spiro-lactam compounds and methods of treating viral infections Inactive 03-Jun-2020 0000000000
AU-2021284376-A1 Spiro-lactam compounds and methods of treating viral infections Pending 03-Jun-2020 0000000000
CA-3184348-A1 Spiro-lactam compounds and methods of treating viral infections using the same Pending 03-Jun-2020 0000000000
US-20230210851-A1 Spiro-lactam compounds and methods of treating viral infections using the same Pending 03-Jun-2020 0000000000
CA-3161742-A1 Methods of treating cognitive impairment associated with neurodegenerative disease Pending 04-Dec-2019 A61K31/438
To view Aptinyx’s complete patent history, request access »

Aptinyx Executive Team (9)

Name Title Board Seat Contact Info
Andy Kidd Chief Executive Officer
Amin Khan Ph.D Vice President, Chemistry Research & Development
You’re viewing 2 of 9 executive team members. Get the full list »

Aptinyx Board Members (13)

Name Representing Role Since
Adam Koppel Ph.D Bain Capital Board Member 000 0000
Gilmore O'Neill Self Board of Director 000 0000
Patrick Enright Longitude Capital Chairman & Board Member 000 0000
Robert Hombach Jr. Naurex Board Member 000 0000
You’re viewing 4 of 13 board members. Get the full list »

Aptinyx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aptinyx ESG

Risk Overview

Risk Rating

Updated June, 13, 2021

25.2 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,042

Rank

00.00

Percentile

Healthcare

Industry

00 of 577

Rank

00.00

Percentile

Medical Services

Subindustry

00 of 100

Rank

00.0

Percentile

To view Aptinyx’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »